Out-of-pocket costs are higher for cancer patients who have a higher stage of disease at diagnosis, data suggest.

If confirmed, our findings may provide a more precise clinical target for definitive trials of PA as a prostate cancer treatment as well as for PA promotion efforts in newly diagnosed prostate cancer ...

Democratic-controlled congressional committees and left-leaning think tanks are significantly more likely than their Republican counterparts to reference research papers, a study suggests.

This study underscores the need for future prospective studies and interventions to address current and impending drug shortages among practices, and a thorough policy approach is necessary to address ...

The FDA has accepted for priority review the resubmitted BLA for tabelecleucel to treat patients 2 years of age and older with EBV+ PTLD who have received at least 1 prior therapy.